Clinical Trials · NCT01867437

Effects of RM-493 on Energy Expenditure in Obese Individuals

Name: Effects of RM-493 on Energy Expenditure in Obese Individuals
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 1Setmelanotide

Phase: Phase 1
Recruitment status: Completed
Sponsor: Rhythm Pharmaceuticals, Inc.
Enrollment: 15
Start date: May 2013
Locations: 1 site, United States
Primary endpoint: Resting energy expenditure measured in a room calorimeter during continuous subcutaneous infusion of RM-493 or placebo in obese healthy subjects

View Setmelanotide compound reference